Prostaglandin E2 impairs osteogenic and facilitates adipogenic differentiation of human bone marrow stromal cells

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 94, Issue , 2015, Pages 91-98

  Noack, Carolin ^a,b   Hempel, Ute ^a   Preissler, Carolin ^a   Dieter, Peter ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Adipogenic differentiation; Dexamethasone; Human bone marrow stromal cells; Inflammation; Osteogenic differentiation; Prostaglandin E2

Indexed keywords

ASCORBIC ACID; CYCLOOXYGENASE 2; DEXAMETHASONE; GLYCEROL 2 PHOSPHATE; PROSTAGLANDIN E2; PROSTAGLANDIN E2 SYNTHETASE 1; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR EP1; PROSTAGLANDIN RECEPTOR EP2; PROSTAGLANDIN RECEPTOR EP4; SYNTHETASE; UNCLASSIFIED DRUG; CULTURE MEDIUM; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PTGER2 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ADIPOGENESIS; ADIPOGENIC DIFFERENTIATION; ARTICLE; BONE DEVELOPMENT; BONE MARROW STROMA CELL; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME REPRESSION; HORMONE ACTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OSTEOBLAST; OSTEOGENIC DIFFERENTIATION; OSTEOGENIC MEDIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; ADULT; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; MALE; MESENCHYMAL STROMA CELL; METABOLISM;

ADIPOGENESIS; ADULT; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA; CYCLOOXYGENASE 2; DEXAMETHASONE; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84924063133     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.11.008     Document Type: Article

References (57)

1. Claes L., Recknagel S., Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat. Rev. Rheumatol. 2012, 8:133-143.
2. Ding J., Ghali O., Lencel P., Broux O., Chauveau C., Devedjian J.C., et al. TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci. 2009, 84:499-504.
3. Hempel U., Matthäus C., Preissler C., Möller S., Hintze V., Dieter P. Artificial matrices with high-sulfated glycosaminoglycans and collagen are anti-inflammatory and pro-osteogenic for human mesenchymal stromal cells. J. Cell. Biochem. 2014, 115:1561-1571. 10.1002/jcb.24814.
4. Pietrogrande L., Raimondo E., Fossali A., Zaolino C. Biological and pharmacological factors influencing the fracture healing. Aging Clin. Exp. Res. 2011, 23(Suppl. 2):S65-S68.
5. Graham S., Gamie Z., Polyzois I., Narvani A.A., Tzafetta K., Tsiridis E., Helioti M., Mantalaris A., Tsiridis E. Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: in vivo and in vitro evidence. Expert Opin. Investig. Drugs 2009, 18:746-766.
6. Bastian O., Pillay J., Alblas J., Leenen L., Koenderman L., Blokhuis T. Systemic inflammation and fracture healing. J. Leukoc. Biol. 2011, 89:669-673.
7. Blackwell K.A., Raisz L.G., Pilbeam C.C. Prostaglandins in bone: bad cop, good cop?. Trends Endocrinol. Metab. 2010, 21:294-301.
8. Thomas M.V., Puleo D.A. Infection, inflammation, and bone regeneration: a paradoxical relationship. J. Dent. Res. 2011, 90:1052-1061.
9. Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier J.P., Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 2011, 7:33-42.
10. Sadie-van Gijsen H., Crowther N.J., Hough F.S., Ferris W.F. The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity. Cell. Mol. Life Sci. 2013, 70:2331-2349.
11. Hardaway A.L., Herroon M.K., Rajagurubandara E., Podgorski I. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev. 2014, 33:527-543.
12. 2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 2010, 42:198-201.
13. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
14. Minamizaki T., Yoshiko Y., Yoshioka H., Kozai K., Aubin J.E., Maeda N. The EP4-ERK-dependent pathway stimulates osteo-adipogenic progenitor proliferation resulting in increased adipogenesis in fetal rat calvaria cell cultures. Prostaglandins Other Lipid Mediat. 2012, 97:97-102.
15. 2 affects osteoblast biology in a dose-dependent manner: an in vitro study. Arch. Oral Biol. 2012, 57:1274-1281.
16. 2 acts via bone marrow macrophages to block PTH-stimulated osteoblast differentiation in vitro. Bone 2013, 56:31-41.
17. Tsutsumi R., Xie C., Wei X., Zhang M., Zhang X., Flick L.M., et al. PGE2 signaling through the EP4 receptor on fibroblasts up-regulates RANKL and stimulates osteolysis. J. Bone Miner. Res. 2009, 24:1753-1762.
18. Pittenger M.F. Mesenchymal stem cells from adult bone marrow. Methods Mol. Biol. 2008, 449:27-44.
19. Kim H.-J. New understanding of glucocorticoid action in bone cells. BMB Rep. 2010, 43:524-529.
20. Eijken M., Koedam M., van Driel M., Buurman C.J., Pols H.A., van Leeuwen J.P. The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol. Cell. Endocrinol. 2006, 248:87-93.
21. Baschant U., Lane N.E., Tuckermann J. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat. Rev. Rheumatol. 2012, 8:645-655.
22. Ratman D., Vanden Berghe W., Dejager L., Libert C., Tavernier J., Beck I.M., De Bosscher K. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol. Cell. Endocrinol. 2013, 380:41-54.
23. Nixon M., Andrew R., Chapman K.E. It takes two to tango: dimerisation of glucocorticoid receptor and its anti-inflammatory functions. Steroids 2013, 78:59-68.
24. Mikami Y., Lww M., Irie S., Honda M.J. Dexamethasone modulates osteogenesis and adipogenesis with regulation of osteix expression in rat calvarial-derived cells. J. Cell. Physiol. 2011, 226:739-748.
25. Wang D., Haile A., Jones L.C. Dexamethasone-induced lipolysis increased the adverse effect of adipocytes on osteoblasts using cells derived from human mesenchymal stem cells. Bone 2013, 53:520-530.
26. Oswald J., Boxberger S., Jørgensen B., Feldmann S., Ehninger G., Bornhäuser M., Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22:377-384.
27. 2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides. Mediat. Inflamm. 1999, 295-303.
28. Scutt A., Berg A., Mayer H. A semiautomated 96-well plate assay for collagen synthesis. Anal. Biochem. 1992, 203:290-294.
29. Fischer U., Hempel U., Becker D., Bierbaum S., Scharnweber D., Worch H., et al. Transforming growth factor beta1 immobilized adsorptively on Ti6Al4V and collagen type I coated Ti6Al4V maintains its biological activity. Biomaterials 2003, 24:2631-2641.
30. Currie G.A. Platelet derived growth-factor requirement for in vitro proliferation of normal and malignant mesenchymal cells. Br. J. Cancer 1981, 43:335-343.
31. Hempel U., Hefti T., Kalbacova M., Wolf-Brandstetter C., Dieter P., Schlottig F. Response of osteoblast-like SAOS-2 cells to zirconia ceramics with different surface topographies. Clin. Oral Implants Res. 2010, 21:174-181.
32. Lutter A.H., Hempel U., Wolf-Brandstetter C., Garbe A., Goettsch C., Hofbauer L., Jessberger R., Dieter P. A novel resorption assay to assess osteoclast function based on an osteoblast-derived native extracellular matrix. J. Cell. Biochem. 2010, 109:1025-1032.
33. Lynch M.P., Capparelli C., Stein J.L., Stein G.S., Lian J.B. Apoptosis during bone-like tissue development. J. Cell. Biochem. 1998, 68:31-49.
34. Lian J.B., Javed A., Zaidi S.K., Lengner C., Montecino M., van Wijnen A.J., et al. Regulatory controls for osteoblasts growth and differentiation: role of Runx/Cbfa/AML factors. Crit. Rev. Eukaryot. Gene Expr. 2004, 14:1-41.
35. Hardaway A.L., Podgorski I. IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med. Chem. 2013, 5:1089-1108.
36. Davies B.S., Beigneux A.P., Fong L.G., Young S.G. New wrinkles in lipoprotein lipase biology. Curr. Opin. Lipidol. 2012, 23:35-42.
37. Kawai M., Rosen C.J. PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat. Rev. Endocrinol. 2010, 6:629-636.
38. Hernández M.V., Guañabens N., Alvarez L., Monegal A., Peris P., Riba J., Ercilla G., Martinez de Osaba M.J., Muñoz-Gómez J. Immuncytochemical evidence on the effects of glucocorticoids on the type I collagen synthesis in human osteoblastic cells. Calcif. Tissue Int. 2004, 74:284-293.
39. Devlin M.J., Rosen C.J. The bone-fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes Endocrinol. 2014, pii: S2213-8587(14):70007-1-70007-5. 10.1016/S2213-8587(14)70007-5.
40. Abdallah B.M., Kassem M. New factors controlling the balance between osteoblastogenesis and adipogenesis. Bone 2012, 50:540-545.
41. Li J., Zhang N., Huang X., Xu J., Fernandes J.C., Dai K., Zhang X. Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation. Cell Death Dis. 2013, 4:e832. 10.1038/cddis.2013.348.
42. Park J.B. Effects of the combination of dexamethasone and fibroblast growth factor-2 on differentiation of osteoprecursor cells. Mol. Med. Rep. 2014, 9:659-662.
43. Hempel U., Möller S., Noack C., Hintze V., Scharnweber D., Schnabelrauch M., Dieter P. Sulfated hyaluronan/collagen I-matrices enhance osteogenic differentiation of human mesenchymal stromal cells in vitro even in the absence of dexamethasone. Acta Biomater. 2012, 8:4064-4072.
44. Mikami Y., Omoteyama K., Kato S., Takagi M. Inductive effects of dexamethasone on the mineralization and the osteoblastic gene expressions in mature osteoblast-like ROS17/2.8 cells. Biochem. Biophys. Res. Commun. 2007, 362:368-373.
45. Rehn A.P., Cerny R., Sugars R.V., Kaukua N., Wendel M. Osteoadherinis upregulated by mature osteoblasts and enhances their in vitro differentiation and mineralization. Calcif. Tissue Int. 2008, 82:454-464.
46. Naito M., Omoteyama K., Mikami Y., Takahashi T., Takagi M. Inhibition of Wnt/β-catenin signaling by dexamethasone promotes adipocyte differentiation in mesenchymal progenitor cells, ROB-C26. Histochem. Cell Biol. 2012, 138:833-845.
47. Ahdjoudj S., Lasmoles F., Oyajobi B.O., Lomri A., Delannoy P., Marie P.J. Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation of multipotential clonal human marrow stromal F/STRO-1(+) cells. J. Cell. Biochem. 2001, 81:32-38.
48. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
49. Fournier T., Fadok V., Henson P.M. Tumor necrosis factor-alpha inversely regulates prostaglandin D2 and prostaglandin E2 production in murine macrophages. Synergistic action of cyclic AMP on cyclooxygenase-2 expression and prostaglandin E2 synthesis. J. Biol. Chem. 1997, 272:31065-31072.
50. Molina-Holgado E., Ortiz S., Molina-Holgado F., Guaza C. Induction of COX-2and PGE(2) biosynthesis by IL-1beta is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. Br. J. Pharmacol. 2000, 131:152-159.
51. Dieter P., Scheibe R., Kamionka S., Kolada A. LPS-induced synthesis and release of PGE2 in liver macrophages: regulation by CPLA2, COX-1, COX-2, and PGE2 synthase. Adv. Exp. Med. Biol. 2002, 507:457-462.
52. Sarrazin P., Bkaily G., Haché R., Patry C., Dumais R., Rocha F.A., de Brum-Fernandes A.J. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot. Essent. Fat. Acids 2001, 64:203-210.
53. Besse A., Trimoreau F., Faucher J.L., Praloran V., Denizot Y. Prostaglandin E2 regulates macrophage colony stimulating factor secretion by human bone marrow stromal cells. Biochim. Biophys. Acta 1999, 1450:444-451.
54. Fortier I., Gallant M.A., Hackett J.A., Patry C., de Brum-Fernandes A.J. Immunolocalization of the prostaglandin E2 receptor subtypes in human bone tissue: differences in foetal, adult normal, osteoporotic and pagetic bone. Prostaglandins Leukot. Essent. Fat. Acids 2004, 70:431-439.
55. 2 in osteoblastic cell lines and adult rat bone tissue. Bone 2001, 28:275-281.
56. Akaogi J., Nozaki T., Satoh M., Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr. Metab. Immune Disord. Drug Targets 2006, 6:383-394.
57. Ninomiya T., Hosoya A., Hiraga T., Koide M., Yamaguchi K., Oida H., Arai Y., Sahara N., Nakamura H., Ozawa H. Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur. J. Pharmacol. 2011, 650:396-402.